Anlotinib Hydrochloride Capsules
Sponsors
The First Affiliated Hospital of Zhengzhou University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sun Yat-sen University, Xianhai Mao, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Conditions
Adjuvant TherapyAdvanced Hepatocellular CarcinomaAdvanced Hepatocellular Carcinoma (HCC)Advanced Lung CarcinomaColorectal CancerDiffuse Large B-cell LymphomaEndometrial CarcinomaHCC
Phase 1
A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib Hydrochloride Capsules for First-line Treatment of Advanced Hepatocellular Carcinoma (HCC).
TerminatedNCT05975645
Start: 2023-08-15End: 2025-06-04Updated: 2025-08-12
A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.
NCT06010901
Start: 2024-01-13End: 2025-07-31Target: 75Updated: 2024-01-23
Phase 2
A Study of Anlotinib Hydrochloride Capsules in Subjects With Diffuse Large B-Cell Lymphoma
NCT04827004
Start: 2021-04-30End: 2022-12-31Target: 30Updated: 2021-04-01
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
NCT04924192
Start: 2021-08-18End: 2023-12-30Target: 126Updated: 2021-09-21
TQB2450 Plus Anlotinib as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Resection
NCT05111366
Start: 2022-01-06End: 2024-05-20Target: 37Updated: 2022-05-04
A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma
NCT05121363
Start: 2021-12-31End: 2023-07-31Target: 113Updated: 2021-11-30
Phase 3
Treatment of Advanced Intrahepatic Cholangiocarcinoma
NCT03940378
Start: 2019-02-01End: 2023-02-01Target: 152Updated: 2019-05-07
Novel Treatment of Advanced Hepatocellular Carcinoma
NCT03950518
Start: 2019-04-10End: 2023-04-10Target: 300Updated: 2019-05-15
A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)
Active, not recruitingNCT04344158
Start: 2020-08-11End: 2026-12-31Target: 648Updated: 2025-02-20
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC)
NCT04964479
Start: 2021-08-06End: 2023-03-31Target: 375Updated: 2021-08-20
A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer
NCT05145218
Start: 2021-09-28End: 2024-12-31Target: 405Updated: 2021-12-08
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
RecruitingNCT07165951
Start: 2025-12-02End: 2028-12-31Target: 566Updated: 2025-12-24
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Not yet recruitingNCT07385079
Start: 2026-03-01End: 2030-01-01Target: 412Updated: 2026-02-03